A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn’s disease (ENACT-2)

2004 ◽  
Vol 127 (1) ◽  
pp. 332 ◽  
Author(s):  
W. Sandborn ◽  
J.-F. Colombel ◽  
R. Enns ◽  
B. Feagan ◽  
S. Hanauer ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Response ◽  
Phase Iii ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

Mo2083 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease

2012 ◽  
Vol 143 (3) ◽  
pp. e26 ◽  
Author(s):  
Stephan R. Targan ◽  
Brian G. Feagan ◽  
Severine Vermeire ◽  
Remo Panaccione ◽  
Gil Y. Melmed ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Clinical trial: vitamin D3 treatment in Crohn’s disease - a randomized double-blind placebo-controlled study

2010 ◽  
Vol 32 (3) ◽  
pp. 377-383 ◽  
Author(s):  
S. P. Jørgensen ◽  
J. Agnholt ◽  
H. Glerup ◽  
S. Lyhne ◽  
G. E. Villadsen ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Vitamin D3 ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

768 A Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Ustekinumab Maintenance Therapy in Moderate - Severe Crohn's Disease Patients: Results From IM-UNITI

2016 ◽  
Vol 150 (4) ◽  
pp. S157-S158 ◽  
Author(s):  
William Sandborn ◽  
Brian G. Feagan ◽  
Christopher Gasink ◽  
Douglas Jacobstein ◽  
Long-Long Gao ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Maintenance Therapy ◽  
Controlled Study ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document